Close Menu

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Tuesday that its second quarter sales dropped 20 percent year over year.

Total sales came in at $7.3 million for the three months ended June 30, down from $9.1 million a year ago. The Omaha, Neb.-based firm attributed the decline to "unusually high test volumes" process in the year-ago period, resulting from a backlog following a LIMS software failure during the first quarter of 2012.

Diagnostic Tools revenues were "slightly higher" compared to a year ago, it added.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.

Nov
13
Sponsored by
Agena Bioscience

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).